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Abstract Shear wave elastography (SWE) shows prom-
ise as an adjunct to greyscale ultrasound examination in
assessing breast masses. In breast cancer, higher lesion
stiffness on SWE has been shown to be associated with
features of poor prognosis. The purpose of this study was to
assess whether lesion stiffness at SWE is an independent
predictor of lymph node involvement. Patients with inva-
sive breast cancer treated by primary surgery, who had
undergone SWE examination were eligible. Data were
retrospectively analysed from 396 consecutive patients.
The mean stiffness values were obtained using the Aix-
plorer ultrasound machine from SuperSonic Imagine Ltd.
Measurements were taken from a region of interest posi-
tioned over the stiffest part of the abnormality. The average
of the mean stiffness value obtained from each of two
orthogonal image planes was used for analysis. Associa-
tions between lymph node involvement and mean lesion
stiffness, invasive cancer size, histologic grade, tumour
type, ER expression, HER-2 status and vascular invasion
were assessed using univariate and multivariate logistic
regression. At univariate analysis, invasive size, histologic
grade, HER-2 status, vascular invasion, tumour type and
mean stiffness were significantly associated with nodal
involvement. Nodal involvement rates ranged from 7 % for
tumours with mean stiffness\50 kPa to 41 % for tumours
with a mean stiffness of [150 kPa. At multivariate ana-
lysis, invasive size, tumour type, vascular invasion, and
mean stiffness maintained independent significance. Mean
stiffness at SWE is an independent predictor of lymph node
metastasis and thus can confer prognostic information
additional to that provided by conventional preoperative
tumour assessment and staging.
Keywords Breast cancer  Prognosis  Elastography 
Metastasis
Introduction
Several large studies have shown that the addition of shear
wave elastography (SWE) to greyscale ultrasound
improves the performance of ultrasound examination in
differentiating benign from malignant breast masses [1–3].
SWE is quantitative and highly reproducible, in contrast to
static elastography [3–6]. The combination of SWE and
greyscale ultrasound has been shown to be highly sensitive;
that is, if both are negative, malignancy is extremely
unlikely (no false-negative cases in a series of 111 pub-
lished in 2012) [3]. It is therefore likely that SWE will be
increasingly used in routine clinical practise.
It has been shown that large invasive size, high histo-
logical grade and vascular invasion are independently
associated with increased stiffness at SWE [7, 8]. These
studies did not show lesion stiffness to be an independent
predictor of nodal status but given the relatively small
numbers, they may have been underpowered for this out-
come. Lymph node status is the most powerful prognostic
indicator in breast cancer [9] and knowledge of lymph node
status influences both surgical management and the use of
systemic therapy (adjuvant and neoadjuvant).
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More accurate identification of likely lymph node
metastases at diagnosis could minimise the need for a
subsequent surgical procedure to clear the axilla following
initial surgery and sentinel node biopsy. A second opera-
tion carries costs and risks, in addition to an inevitable
delay in time to initiation of adjuvant chemotherapy, which
should be given in a timely fashion to optimise long-term
patient outcome [10].
The aim of this study was to determine, in a large series
of patients with primary invasive breast cancer treated
initially by surgery, whether SWE findings could inde-
pendently predict lymph node status when taking known
predictors of nodal status such as invasive size, histological
grade and vascular invasion status [11, 12] into account. If
SWE finding are predictive of lymph node involvement
this may be clinically useful in selecting patients for neo-
adjuvant chemotherapy (NACT), as the established pre-
dictors of nodal involvement are only definitively available
post operatively, and ultrasound guided percutaneous
biopsy of nodes with abnormal ultrasound morphology
only establishes a diagnosis of nodal metastases in around
50 % of cases shown to be positive at surgery [13].
Patients and methods
SWE has been part of routine breast ultrasound examina-
tions at our institution since November 2009. In accordance
with the applicable UK National Research Ethics Service
guidance [14], ethical approval for the study was not
required. Consecutive patients with invasive breast cancer
identified during ultrasound scans using the Aixplorer
ultrasound system (SuperSonic Imagine, Aix en Provence,
France) between 19/04/2010 and 12/12/2012 and treated by
primary surgery were included in this study.
The sample included women with symptoms and
women with screen-detected abnormalities. All women
were scanned and biopsied by one of three breast radiol-
ogists or an advanced radiography practitioner trained to
perform and interpret breast ultrasonography. These prac-
titioners had between 5 and 20 years of breast ultrasound
experience and had at least 3 months experience of per-
forming SWE of solid breast lesions.
Greyscale and elastography images were obtained dur-
ing the standard ultrasound appointment. The elastography
colour map findings were taken into account in the diag-
nostic management of the patients but the quantitative
measurements were produced and analysed later to mini-
mise impact on workflow. The elasticity values were
obtained by moving a delineated region of interest (ROI)
over the colour map. As the ROI moves, the readings
change in real time so the ROI can be positioned over the
part of the image showing the stiffest tissue.
Four elastography images—in each of two orthogonal
planes—were taken of each lesion. The transducer was
held still over the lesion for about 10 s to allow the shear
wave image to build up. If the patient was breathing
heavily, she was asked to hold her breath during acquisi-
tion. Mean ROI stiffness values (kPa) from the four images
were used for analysis.
Analysis was based on histological data points from
pathological examination of the resected specimen: histo-
logical grade, tumour type, invasive size, vascular inva-
sion, ER, HER-2 status and lymph node stage. These were
assessed according to UK national guidelines [15, 16].
Macro-metastases were counted as node positive while
micro-metastases and isolated tumour cells were counted
as node negative. Univariate and multivariate logistic
regression were used to establish the significance of asso-
ciations of histological and shear wave findings with lymph
node status.
Results
The sample comprised 396 patients; 217 presented with
symptoms, whereas 179 had cancers detected by mam-
mographic screening. The patients’ ages ranged from 31 to
92 years with a median of 62 years. The histological
characteristics of the study group are shown in Table 1.
The median invasive tumour size was 19 mm, 28 % of
patients had lymph node metastases and 27 % had vascular
invasion. The tumour stiffness values according to nodal
status are shown in Table 2. Nodal status according to
range of mean stiffness values is shown in Table 3. Nodal
metastasis rates ranged from 7 % for tumours with mean
stiffness \50 kPa to 41 % for tumours with a mean stiff-
ness of [150 kPa.
At univariate analysis, invasive size, histological grade,
HER-2 status, vascular invasion, tumour type and mean
Table 1 Histological features
of the 396 invasive cancers in
the study group
a 6 patients had unknown HER
2 status
Histological
feature
Number
(%)
Grade 1 55 (14)
Grade 2 167 (42)
Grade 3 174 (44)
Node positive 112 (28)
Vascular invasion 105 (27)
HER 2 positivea 36 (9)
ER positive 330 (83)
PR positive 271 (68)
Invasive size
\15 mm
131 (33)
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stiffness were significantly associated with nodal involve-
ment while ER, PR and age were not (Table 4). At mul-
tivariate analysis, invasive size, tumour type, vascular
invasion and mean stiffness maintained independent sig-
nificance in predicting nodal involvement while ER, PR,
HER-2, age and histological grade did not (Table 5).
Discussion
We have found that mean stiffness as measured by SWE is
an independent predictor for nodal involvement in breast
cancer in addition to well-established predictors such as
invasive size and vascular invasion status. In contrast to
previous studies, [11, 12] histological grade was not an
independent predictor of nodal involvement on multivari-
ate analysis. This may be because stiffness on SWE is
associated with histological grade [7, 8].
The stiff tissue associated with invasive breast cancer is
usually seen at the periphery of the tumour, extending into
the peri-tumoural stroma. Often, the tumour itself is less
stiff than the surrounding stroma. Although not proven, it is
likely that the stiffness represents abnormal tumour-asso-
ciated collagen, which has been shown to exhibit increased
collagen crosslinking and abnormal alignment. These col-
lagen abnormalities have recently been shown to have
independent prognostic significance [17, 18]. In recent
years, stromal gene signatures, and components such as
Caveolin 1 and LOX 2, have been shown to be important
prognostic and predictive indicators in breast cancer [19–
22]. It is possible that the peri-tumoural stromal stiffness
represents an imaging surrogate for some of these stromal
processes. As these stromal prognostic indicators are not
measured by the conventional predictors of nodal
involvement, such as invasive size and histological grade,
it is not surprising that stromal stiffness has independent
predictive significance. Vascular invasion, another well-
established predictive factor for axillary lymph node
metastasis in breast cancer, has been shown to have a
strong relationship with stromal stiffness on SWE [7, 8].
Like SWE stiffness, vascular invasion is also most com-
monly seen at the tumour–stromal interface [23]. The
independence of vascular invasion and stromal stiffness as
predictors of nodal metastasis suggests that the predictive
power of stromal stiffness is mediated by other factors in
addition to vascular invasion.
Previous SWE studies have found that increased stiff-
ness is associated with nodal metastases on univariate
analysis [7, 8]. However, these studies did not show SWE
stiffness to be an independent predictor of lymph node
metastasis on multivariate analysis. This difference in
findings compared to the current study may reflect insuf-
ficient statistical power resulting from the lower participant
Table 2 Mean stiffness (kPa) values of 396 breast cancers by nodal
status
Range of mean
stiffness values
(kPa)
Mean of mean
stiffness values
(kPa)
Median of mean
stiffness values
(kPa)
Node negative
(n = 284)
14–281 114 105
1–3 nodes
positive
(n = 78)
31–281 141 130
4 or more
nodes
positive
(n = 34)
77–265 156 149
Table 3 Nodal status according to mean stiffness value (range)
Mean stiffness
range (kPa)
Node negative
n (%)
Node positive
n (%)
\50 27 (93) 2 (7)
50–99 101 (78) 28 (22)
100–149 83 (72) 32 (28)
[150 73 (59) 50 (41)
Table 4 Univariate logistic regression
Dependent parameter Independent parameter p value
Nodal Involvement (yes/no) Age (years) 0.6083
ER (binary) 0.1739
HER2 status 0.0408
Invasive size (mm) \0.0001
PR (binary) 0.0930
Stiffness reading \0.0001
Tumour grade \0.0001
Tumour type (classified) 0.0020
Vascular invasion \0.0001
Table 5 Multivariate logistic regression
Dependent parameter Independent parameter p value
Nodal involvement (yes/no) Age (years) 0.7655
ER (binary) 0.4626
HER2 status 0.4570
Invasive size (mm) \0.0001
PR (binary) 0.3698
Stiffness reading 0.0350
Tumour grade 0.6300
Tumour type (classified) 0.0104
Vascular invasion 0.0027
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numbers (166 and 100, compared to 396 in this study). The
larger of the previous studies took only one shear wave
measurement from each tumour while the current study
took four, further increasing the statistical power of our
study.
The main weakness of the current study is that it is from a
single centre with a special interest in SWE. We do not know
whether such results are reproducible in other clinical cen-
tres. Although the analysis was retrospective, the SWE data
were acquired prospectively as part of our routine clinical
practise, and recorded before core biopsy results or surgical
pathology were known.
In current practise, ultrasound guided needle biopsy of
axillary lymph nodes with abnormal cortical morphology
allows pre-operative diagnosis of axillary metastases in
only around 50 % of women [13]. Preoperative diagnosis
of nodal metastases is valuable as, when added to tumour
size estimation on imaging and histological grading on core
biopsy, it refines preoperative prognostication [24, 25].
This can facilitate the use of NACT to down-stage tumours
prior to surgery, or to identify more accurately at diagnosis
the most appropriate axillary surgery for patients following
NACT. There remains some debate regarding the optimal
timing of sentinel lymph node biopsy (SLNB) in patients
receiving NACT [26], and the false negative rate of SLNB
after neoadjuvant chemotherapy may be higher than would
be deemed acceptable [27]; consequently, any tool to help
facilitate more accurate staging of the axilla at diagnosis
would be valuable. Our findings suggest that SWE has the
potential to refine preoperative prognostication, and thus
help improve decision making with regard to neo-adjuvant
chemotherapy and management of the axilla.
In conclusion, mean stiffness at SWE is an independent
predictor of lymph node metastasis in women with invasive
breast cancer and thus can contribute additional, non-
invasive prognostic information compared to conventional
preoperative tumour assessment and staging.
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